We're seeking to fill two roles: a postdoc and a research assistant. Both will focus on resistance mechanisms in brain tumour models using various approaches (in vivo, spatial omics, CRISPR). Please apply if this aligns with your previous experience!
shorturl.at/hZ6mG
Excited and frankly nervous to be running the Cambridge Half Marathon tomorrow morning, having only signed up 4 weeks ago. But proud to be running for amazing Centre 33, which does so much for young people in Cambridgeshire. 💪🏼 www.justgiving.com/page/simon-r...
2025 is drawing to a close and what a year it’s been! 🌟
From growing our community to advancing research and transforming clinical practice, it’s been a year full of progress.
Here are some of our 2025 highlights. 👇
Season's greetings to all our members, partners and supporters!
Brian Huntly and I are looking to recruit a postdoc to investigate a promising novel therapeutic target in B-ALL @scicambridge.bsky.social. This new CRUK-funded project will involve collaboration with Prof Sir Steve Jackson's group @cruk-ci.bsky.social and the CRUK Functional Genomics centre.
Delighted to help @crukpolicy.bsky.social promote their #BackTheBreakthroughs campaign in Parliament today. Wide-ranging discussions, including on crucial work to reduce regulatory hurdles for trials, improve access to new therapeutics and support clinical academics.
Brian Huntly and I are looking to recruit a postdoc to investigate a promising novel therapeutic target in B-ALL @scicambridge.bsky.social. This new CRUK-funded project will involve collaboration with Prof Sir Steve Jackson's group @cruk-ci.bsky.social and the CRUK Functional Genomics centre.
A decade of bold ideas, brilliant minds & real impact. 💡
Our John Goldman Fellowships are driving progress in leukaemia research, from identifying new drug targets to repurposing existing medicines.
Read more: www.leukaemiauk.org.uk/stories/a-de...
On my way back from a fabulous day of science and catching up with friends and colleagues at the UKALL Research Network update day. Great to see so much progress. 👍
It is with great sadness that the University shares the news of the death of Professor Sir John Gurdon, founder of the @gurdoninstitute.bsky.social
Read our tribute to the visionary Nobel Laureate and watch an interview from 2012, just after he won: https://bit.ly/4mM8o3r
Great to host our new @stcatharines.bsky.social medics before their first college dinner 🩺😷🚑🩻⚕️
Thank you @leukaemiauk.bsky.social for the invitation to #WCD2025. 😋 It was great to share some of our work and humbling to hear the story of 4 year old Billie the Brave. Congrats on raising so much in one evening for life changing leukaemia research! ❤️
Thanks to @leukaemiauk.bsky.social for the opportunity to contribute to this amazing session. So important to link patient experiences with our science and translational research
💙 Between now & the UCAS application deadline on 15 Oct, it’s worth checking if you're eligible for the Finlay Family Bursary, which covers all tuition fees & a living allowance for a St Catharine’s student from Scotland for all 3 or 4 years of an undergraduate degree: shorturl.at/K0RuE 3/3
LS, an emergent form of acute leukemia relapse after antigen-targeted therapy, primarily in B-ALL, has dismal outcomes. buff.ly/59xI6qv #hemesky
Congrats! Really exciting work.
I feel a student granulomatous round of unknown aetiology coming on.
I’m looking for a Postdoc to join my new lab @pdncambridge.bsky.social on an MRC-funded project and explore maternal inter-organ communication with a focus on the mammary gland, using a novel mouse model.
📍 Tenure: 3 years
⏳ Deadline: 15 August 2025
Please RT 🙏
👉 www.jobs.cam.ac.uk/job/51984/
No trains? No problem! Wacky races down to The City of London with these amazing @crukcamcentre.bsky.social entrepreneurial scientists just in time for the CRUK Innovation and Enterprise awards. Thank you @crhorizons.bsky.social 🥂🎉🙏
Absolute honour to attend Marc Mansour’s @marcmansour.bsky.social inaugural lecture at ICH today. An inspiring clinician scientist and all round legend. #researchculture
Fabulous news Geula. Congratulations!! 🥂
Really exciting to co-organise the 20 year graduation reunion for Oxford medical school last night. Wonderful to reunite with old friends and hear retired DoS Tim Lancaster speak powerfully about how caring is at the heart of good medicine 💊❤️
Best night of the year !
Farewell dinner for the new doctors from @stcatharines.bsky.social
Interviewed them 7 years ago.
Watched them blossom for 6 years.
Now they’re amazing!
Thanks to the editorial team @natcomms.nature.com for including our recent paper in their Editors' Highlights in the field of Cancer Biology 🎉
Two charts present survival rates for childhood leukemia over time, specifically focusing on Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML). In the top panel, for ALL, a series of curved lines represent overall survival rates plotted against years since diagnosis. The lines show a marked increase in survival rates from the late 1960s, when only 14% of children survived more than five years post-diagnosis, to around 94% in the 2010s. Key intervals are labeled, with different colors indicating different periods of diagnosis, ranging from 1972-1975 to 2010-2015. The bottom panel illustrates survival rates for AML, which are consistently lower overall compared to ALL. Like the top graph, it features several colored lines indicating specific periods. The highest point noted indicates a survival rate of 65%. The graph captures trends in survival as well, showing gradual improvement over time, from 1975-1977 up to 2011-2017. Data sources for these visualizations are cited at the bottom: Mignon Loh et al. (2023) for ALL and Todd M Cooper et al. (2023) for AML, both from the Children's Oncology Group. The chart is published by Our World in Data, and licensed under Creative Commons by the author, Saloni Dattani.
I wrote a new piece on how much progress has been made in treating childhood leukemia.
The answer is: quite a lot!
Before the 1970s, fewer than 10% of children diagnosed survived 5 years after diagnosis.
Now most are cured and around 85% survive that long.
ourworldindata.org/childhood-le...
What an inspiring evening hearing from patients, researchers and fundraisers at an Evening with Leukaemia UK.
So much progress. So much to do
@leukaemiauk.bsky.social
Thanks to Chris Smith and the Naked Scientists for the invitation to discuss our work - fully clothed 🤓
www.thenakedscientists.com/articles/int...
And that’s a wrap. 20 supervisons in biochemistry and genetics for the Catz @stcatharines.bsky.social first year medics. Good luck in the exams!
12/12 Special thanks to the patient donors and samples from VIVO Biobank and of course Brian Huntly & group 🤗 #CSCI @crukcamcentre.bsky.social | Work in my group is largely funded by Cancer Research UK #CRUK, Leukaemia UK
@leukaemiauk.bsky.social and the European Hematology Association. 🙏🏻
11/12 Lots of thanks for help with this multidisciplinary project, including to stellar PhD Alicia Garcia-Gimenez and RA Jon Ditcham for all their hard work | to amazing collaborators @koulman.bsky.social @mitoredox.bsky.social @marcmansour.bsky.social
10/12 Excitingly, the CREBBP inhibitor Inobrodib has already been tested in combination with Venetoclax in AML, confirming safety. We therefore think this could be a novel, safe, oral approach that could complement current chemo- and immunotherapies, improving outcomes and reducing toxicity.
